Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Posttranscriptional regulation of UGT2B10 hepatic expression and activity by alternative splicing.

Labriet A, Allain EP, Rouleau M, Audet-Delage Y, Villeneuve L, Guillemette C.

Drug Metab Dispos. 2018 Feb 9. pii: dmd.117.079921. doi: 10.1124/dmd.117.079921. [Epub ahead of print]

PMID:
29438977
2.

Immunosuppressive Mesenchymal Stromal Cells Derived from Human-Induced Pluripotent Stem Cells Induce Human Regulatory T Cells In Vitro and In Vivo.

Roux C, Saviane G, Pini J, Belaïd N, Dhib G, Voha C, Ibáñez L, Boutin A, Mazure NM, Wakkach A, Blin-Wakkach C, Rouleau M.

Front Immunol. 2018 Jan 25;8:1991. doi: 10.3389/fimmu.2017.01991. eCollection 2017.

3.

microRNA-184 Induces a Commitment Switch to Epidermal Differentiation.

Nagosa S, Leesch F, Putin D, Bhattacharya S, Altshuler A, Serror L, Amitai-Lange A, Nasser W, Aberdam E, Rouleau M, Tattikota SG, Poy MN, Aberdam D, Shalom-Feuerstein R.

Stem Cell Reports. 2017 Dec 12;9(6):1991-2004. doi: 10.1016/j.stemcr.2017.10.030. Epub 2017 Nov 30.

4.

Quantitative profiling of the UGT transcriptome in human drug-metabolizing tissues.

Tourancheau A, Rouleau M, Guauque-Olarte S, Villeneuve L, Gilbert I, Droit A, Guillemette C.

Pharmacogenomics J. 2017 Apr 25. doi: 10.1038/tpj.2017.5. [Epub ahead of print]

5.

Endogenous Protein Interactome of Human UDP-Glucuronosyltransferases Exposed by Untargeted Proteomics.

Rouleau M, Audet-Delage Y, Desjardins S, Rouleau M, Girard-Bock C, Guillemette C.

Front Pharmacol. 2017 Feb 3;8:23. doi: 10.3389/fphar.2017.00023. eCollection 2017.

6.

Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models.

Kenmogne LC, Roy J, Maltais R, Rouleau M, Neveu B, Pouliot F, Poirier D.

PLoS One. 2017 Feb 9;12(2):e0171871. doi: 10.1371/journal.pone.0171871. eCollection 2017.

7.

Cross-Talk between Alternatively Spliced UGT1A Isoforms and Colon Cancer Cell Metabolism.

Audet-Delage Y, Rouleau M, Rouleau M, Roberge J, Miard S, Picard F, Têtu B, Guillemette C.

Mol Pharmacol. 2017 Mar;91(3):167-177. doi: 10.1124/mol.116.106161. Epub 2017 Jan 3.

8.

Inflammatory Osteoclasts Prime TNFα-Producing CD4+ T Cells and Express CX3 CR1.

Ibáñez L, Abou-Ezzi G, Ciucci T, Amiot V, Belaïd N, Obino D, Mansour A, Rouleau M, Wakkach A, Blin-Wakkach C.

J Bone Miner Res. 2016 Oct;31(10):1899-1908. doi: 10.1002/jbmr.2868. Epub 2016 Jun 30.

9.

Divergent Expression and Metabolic Functions of Human Glucuronosyltransferases through Alternative Splicing.

Rouleau M, Tourancheau A, Girard-Bock C, Villeneuve L, Vaucher J, Duperré AM, Audet-Delage Y, Gilbert I, Popa I, Droit A, Guillemette C.

Cell Rep. 2016 Sep 27;17(1):114-124. doi: 10.1016/j.celrep.2016.08.077.

10.

CT dose reduction: approaches, strategies and results from a province-wide program in Quebec.

Nassiri MA, Rouleau M, Després P.

J Radiol Prot. 2016 Jun 6;36(2):346-362. [Epub ahead of print]

PMID:
27270762
11.

Osteoimmune Interactions in Inflammatory Bowel Disease: Central Role of Bone Marrow Th17 TNFα Cells in Osteoclastogenesis.

Wakkach A, Rouleau M, Blin-Wakkach C.

Front Immunol. 2015 Dec 18;6:640. doi: 10.3389/fimmu.2015.00640. eCollection 2015. Review.

12.

Modeling Andersen's Syndrome in Human Induced Pluripotent Stem Cells.

Pini J, Rouleau M, Desnuelle C, Sacconi S, Bendahhou S.

Stem Cells Dev. 2016 Jan 15;25(2):151-9. doi: 10.1089/scd.2015.0258. Epub 2015 Dec 30.

PMID:
26573604
13.

Poly(ADP-ribosyl)ation-dependent Transient Chromatin Decondensation and Histone Displacement following Laser Microirradiation.

Strickfaden H, McDonald D, Kruhlak MJ, Haince JF, Th'ng JP, Rouleau M, Ishibashi T, Corry GN, Ausio J, Underhill DA, Poirier GG, Hendzel MJ.

J Biol Chem. 2016 Jan 22;291(4):1789-802. doi: 10.1074/jbc.M115.694992. Epub 2015 Nov 11.

14.

Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential.

Margaillan G, Rouleau M, Klein K, Fallon JK, Caron P, Villeneuve L, Smith PC, Zanger UM, Guillemette C.

Drug Metab Dispos. 2015 Sep;43(9):1331-5. doi: 10.1124/dmd.115.065391. Epub 2015 Jun 15.

15.

Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA sequencing.

Tourancheau A, Margaillan G, Rouleau M, Gilbert I, Villeneuve L, Lévesque E, Droit A, Guillemette C.

Pharmacogenomics J. 2016 Feb;16(1):60-70. doi: 10.1038/tpj.2015.20. Epub 2015 Apr 14.

16.

Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells.

Moussaieff A, Rouleau M, Kitsberg D, Cohen M, Levy G, Barasch D, Nemirovski A, Shen-Orr S, Laevsky I, Amit M, Bomze D, Elena-Herrmann B, Scherf T, Nissim-Rafinia M, Kempa S, Itskovitz-Eldor J, Meshorer E, Aberdam D, Nahmias Y.

Cell Metab. 2015 Mar 3;21(3):392-402. doi: 10.1016/j.cmet.2015.02.002.

17.

Local mitochondrial-endolysosomal microfusion cleaves voltage-dependent anion channel 1 to promote survival in hypoxia.

Brahimi-Horn MC, Lacas-Gervais S, Adaixo R, Ilc K, Rouleau M, Notte A, Dieu M, Michiels C, Voeltzel T, Maguer-Satta V, Pelletier J, Ilie M, Hofman P, Manoury B, Schmidt A, Hiller S, Pouysségur J, Mazure NM.

Mol Cell Biol. 2015 May;35(9):1491-505. doi: 10.1128/MCB.01402-14. Epub 2015 Feb 17.

18.

Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues.

Margaillan G, Rouleau M, Fallon JK, Caron P, Villeneuve L, Turcotte V, Smith PC, Joy MS, Guillemette C.

Drug Metab Dispos. 2015 Apr;43(4):611-9. doi: 10.1124/dmd.114.062877. Epub 2015 Feb 3.

19.

Effectiveness of monetary incentives to recruit family physicians as study subjects: a randomized controlled trial.

Giguere AM, Labrecque M, Borduas F, Rouleau M.

BMC Res Notes. 2015 Jan 23;8:15. doi: 10.1186/s13104-014-0969-8.

20.

Bone marrow Th17 TNFα cells induce osteoclast differentiation, and link bone destruction to IBD.

Ciucci T, Ibáñez L, Boucoiran A, Birgy-Barelli E, Pène J, Abou-Ezzi G, Arab N, Rouleau M, Hébuterne X, Yssel H, Blin-Wakkach C, Wakkach A.

Gut. 2015 Jul;64(7):1072-81. doi: 10.1136/gutjnl-2014-306947. Epub 2014 Oct 8.

PMID:
25298539
21.

Roles of osteoclasts in the control of medullary hematopoietic niches.

Blin-Wakkach C, Rouleau M, Wakkach A.

Arch Biochem Biophys. 2014 Nov 1;561:29-37. doi: 10.1016/j.abb.2014.06.032. Epub 2014 Jul 3. Review.

PMID:
24998177
22.

Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications.

Guillemette C, Lévesque É, Rouleau M.

Clin Pharmacol Ther. 2014 Sep;96(3):324-39. doi: 10.1038/clpt.2014.126. Epub 2014 Jun 12.

23.

Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway.

Lévesque E, Laverdière I, Audet-Walsh E, Caron P, Rouleau M, Fradet Y, Lacombe L, Guillemette C.

Clin Cancer Res. 2014 Jun 1;20(11):2971-83. doi: 10.1158/1078-0432.CCR-13-2567. Epub 2014 Mar 28.

24.

Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity.

Fernández-Marcelo T, Frías C, Pascua I, de Juan C, Head J, Gómez A, Hernando F, Jarabo JR, Díaz-Rubio E, Torres AJ, Rouleau M, Benito M, Iniesta P.

J Exp Clin Cancer Res. 2014 Feb 15;33:19. doi: 10.1186/1756-9966-33-19.

25.

Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.

Lévesque É, Laverdière I, Lacombe L, Caron P, Rouleau M, Turcotte V, Têtu B, Fradet Y, Guillemette C.

Clin Cancer Res. 2014 Feb 1;20(3):576-84. doi: 10.1158/1078-0432.CCR-13-1100. Epub 2013 Nov 25.

26.

Vero/CHOK1, a novel mixture of cell lines that is optimal for the rescue of influenza A vaccine seeds.

Medina J, Guillot V, Totain E, Rouleau M, Sodoyer R, Moste C, Legastelois I.

J Virol Methods. 2014 Feb;196:25-31. doi: 10.1016/j.jviromet.2013.09.007. Epub 2013 Oct 23.

PMID:
24161812
27.

Angiomodulin is required for cardiogenesis of embryonic stem cells and is maintained by a feedback loop network of p63 and Activin-A.

Wolchinsky Z, Shivtiel S, Kouwenhoven EN, Putin D, Sprecher E, Zhou H, Rouleau M, Aberdam D.

Stem Cell Res. 2014 Jan;12(1):49-59. doi: 10.1016/j.scr.2013.09.015. Epub 2013 Oct 6.

28.

Human health impacts of biodiesel use in on-road heavy duty diesel vehicles in Canada.

Rouleau M, Egyed M, Taylor B, Chen J, Samaali M, Davignon D, Morneau G.

Environ Sci Technol. 2013 Nov 19;47(22):13113-21. doi: 10.1021/es4023859. Epub 2013 Nov 8.

PMID:
24143909
29.

Dual roles for splice variants of the glucuronidation pathway as regulators of cellular metabolism.

Rouleau M, Roberge J, Bellemare J, Guillemette C.

Mol Pharmacol. 2014 Jan;85(1):29-36. doi: 10.1124/mol.113.089227. Epub 2013 Oct 18.

30.

The relative protein abundance of UGT1A alternative splice variants as a key determinant of glucuronidation activity in vitro.

Rouleau M, Roberge J, Falardeau SA, Villeneuve L, Guillemette C.

Drug Metab Dispos. 2013 Apr;41(4):694-7. doi: 10.1124/dmd.112.050468. Epub 2013 Jan 29.

31.

Reprogramming cellular events by poly(ADP-ribose)-binding proteins.

Krietsch J, Rouleau M, Pic É, Ethier C, Dawson TM, Dawson VL, Masson JY, Poirier GG, Gagné JP.

Mol Aspects Med. 2013 Dec;34(6):1066-87. doi: 10.1016/j.mam.2012.12.005. Epub 2012 Dec 23. Review.

32.

Validation of a new questionnaire with generic and disease-specific qualities: the McGill COPD Quality of Life Questionnaire.

Pakhale S, Wood-Dauphinee S, Spahija A, Collet JP, Maltais F, Bernard S, Baltzan M, Rouleau M, Bourbeau J; Respiratiory Network of the FRSQ.

Can Respir J. 2012 Nov-Dec;19(6):367-72.

33.

Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression.

Lévesque É, Huang SP, Audet-Walsh É, Lacombe L, Bao BY, Fradet Y, Laverdière I, Rouleau M, Huang CY, Yu CC, Caron P, Guillemette C.

Clin Cancer Res. 2013 Feb 1;19(3):699-709. doi: 10.1158/1078-0432.CCR-12-2812. Epub 2012 Nov 27.

34.

Protein-protein interactions between the bilirubin-conjugating UDP-glucuronosyltransferase UGT1A1 and its shorter isoform 2 regulatory partner derived from alternative splicing.

Rouleau M, Collin P, Bellemare J, Harvey M, Guillemette C.

Biochem J. 2013 Feb 15;450(1):107-14. doi: 10.1042/BJ20121594.

PMID:
23148825
35.

PARP activation regulates the RNA-binding protein NONO in the DNA damage response to DNA double-strand breaks.

Krietsch J, Caron MC, Gagné JP, Ethier C, Vignard J, Vincent M, Rouleau M, Hendzel MJ, Poirier GG, Masson JY.

Nucleic Acids Res. 2012 Nov 1;40(20):10287-301. doi: 10.1093/nar/gks798. Epub 2012 Aug 31.

36.

Structural biology. PARP-1 activation--bringing the pieces together.

Gagné JP, Rouleau M, Poirier GG.

Science. 2012 May 11;336(6082):678-9. doi: 10.1126/science.1221870. No abstract available.

PMID:
22582250
37.

Expression of a truncated active form of VDAC1 in lung cancer associates with hypoxic cell survival and correlates with progression to chemotherapy resistance.

Brahimi-Horn MC, Ben-Hail D, Ilie M, Gounon P, Rouleau M, Hofman V, Doyen J, Mari B, Shoshan-Barmatz V, Hofman P, Pouysségur J, Mazure NM.

Cancer Res. 2012 Apr 15;72(8):2140-50. doi: 10.1158/0008-5472.CAN-11-3940. Epub 2012 Mar 2.

38.

microRNA-34a regulates neurite outgrowth, spinal morphology, and function.

Agostini M, Tucci P, Steinert JR, Shalom-Feuerstein R, Rouleau M, Aberdam D, Forsythe ID, Young KW, Ventura A, Concepcion CP, Han YC, Candi E, Knight RA, Mak TW, Melino G.

Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21099-104. doi: 10.1073/pnas.1112063108. Epub 2011 Dec 12.

39.

Regulation of skin aging and heart development by TAp63.

Paris M, Rouleau M, Pucéat M, Aberdam D.

Cell Death Differ. 2012 Feb;19(2):186-93. doi: 10.1038/cdd.2011.181. Epub 2011 Dec 9. Review.

40.

[Unexpected role for p63 during heart development: one phenotype can hide another one].

Rouleau M, Pucéat M, Aberdam D.

Med Sci (Paris). 2011 Oct;27(10):905-9. doi: 10.1051/medsci/20112710023. Epub 2011 Oct 21. Review. French. No abstract available.

41.

TAp63 is important for cardiac differentiation of embryonic stem cells and heart development.

Rouleau M, Medawar A, Hamon L, Shivtiel S, Wolchinsky Z, Zhou H, De Rosa L, Candi E, de la Forest Divonne S, Mikkola ML, van Bokhoven H, Missero C, Melino G, Pucéat M, Aberdam D.

Stem Cells. 2011 Nov;29(11):1672-83. doi: 10.1002/stem.723.

42.

Combining both generic and disease-specific properties: development of the McGill COPD quality of life questionnaire.

Pakhale S, Wood-Dauphinee S, Spahija J, Collet JP, Maltais F, Bernard S, Baltzan M, Rouleau M, Bourbeau J.

COPD. 2011 Aug;8(4):255-63. doi: 10.3109/15412555.2011.578600. Epub 2011 Jul 5.

PMID:
21728790
43.

A key role for poly(ADP-ribose) polymerase 3 in ectodermal specification and neural crest development.

Rouleau M, Saxena V, Rodrigue A, Paquet ER, Gagnon A, Hendzel MJ, Masson JY, Ekker M, Poirier GG.

PLoS One. 2011 Jan 17;6(1):e15834. doi: 10.1371/journal.pone.0015834.

44.

PARP-3 and APLF function together to accelerate nonhomologous end-joining.

Rulten SL, Fisher AE, Robert I, Zuma MC, Rouleau M, Ju L, Poirier G, Reina-San-Martin B, Caldecott KW.

Mol Cell. 2011 Jan 7;41(1):33-45. doi: 10.1016/j.molcel.2010.12.006.

45.

Immunohistochemical expression of conjugating UGT1A-derived isoforms in normal and tumoral drug-metabolizing tissues in humans.

Bellemare J, Rouleau M, Harvey M, Popa I, Pelletier G, Têtu B, Guillemette C.

J Pathol. 2011 Feb;223(3):425-35. doi: 10.1002/path.2805. Epub 2010 Oct 29.

46.

Alternatively spliced products of the UGT1A gene interact with the enzymatically active proteins to inhibit glucuronosyltransferase activity in vitro.

Bellemare J, Rouleau M, Girard H, Harvey M, Guillemette C.

Drug Metab Dispos. 2010 Oct;38(10):1785-9. doi: 10.1124/dmd.110.034835. Epub 2010 Jul 7.

47.

Investigation of PARP-1, PARP-2, and PARG interactomes by affinity-purification mass spectrometry.

Isabelle M, Moreel X, Gagné JP, Rouleau M, Ethier C, Gagné P, Hendzel MJ, Poirier GG.

Proteome Sci. 2010 Apr 13;8:22. doi: 10.1186/1477-5956-8-22.

48.

PARP inhibition: PARP1 and beyond.

Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG.

Nat Rev Cancer. 2010 Apr;10(4):293-301. doi: 10.1038/nrc2812. Epub 2010 Mar 4. Review.

49.

Alternative-splicing forms of the major phase II conjugating UGT1A gene negatively regulate glucuronidation in human carcinoma cell lines.

Bellemare J, Rouleau M, Harvey M, Têtu B, Guillemette C.

Pharmacogenomics J. 2010 Oct;10(5):431-41. doi: 10.1038/tpj.2009.64. Epub 2009 Dec 8.

PMID:
19997083
50.

Modulation of the human glucuronosyltransferase UGT1A pathway by splice isoform polypeptides is mediated through protein-protein interactions.

Bellemare J, Rouleau M, Harvey M, Guillemette C.

J Biol Chem. 2010 Feb 5;285(6):3600-7. doi: 10.1074/jbc.M109.083139. Epub 2009 Dec 8.

Supplemental Content

Loading ...
Support Center